Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response

This document outlines key considerations for the use of fractional dosing with intradermal administration of the MVA-BN mpox vaccine in response to ongoing mpox outbreaks. In light of the limited availability of vaccine and current WHO recommendations, national authorities may, as a temporary outbreak response measure, consider administering MVA-BN vaccine via intradermal injection at a reduced dose to protect individuals at risk of exposure.